文献速递流行病学与生物统计临床试验与 GCP

COVID-19冠状病毒研究方法学质量整体偏低:以氯喹/羟氯喹研究为例

COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine.
PubMed 文献 · J Clin Epidemiol · 2020-04-21

该文评述COVID-19研究的方法学质量,以氯喹/羟氯喹(联合阿奇霉素)研究为切入点。检索MEDLINE、EMBASE及medRxiv至2020年4月3日,共纳入6项研究(3项随机对照试验、3项观察性研究)。作者指出COVID-19研究方法学很差、报告稀疏,缺乏患者重要结局,紧急疫情不能将缺陷方法变为可信结果。

要点

  • 氯喹/羟氯喹相关COVID-19研究仅6项,方法学质量差、报告稀疏。
  • 缺乏患者重要结局的报告,难以支持决策优先级判断。
  • 紧急疫情不改变缺陷方法与数据的不可信性,仍需稳健对照研究。

核心结论

  • 氯喹/羟氯喹领域的COVID-19研究方法学质量很差,且这一现象在COVID-19潜在治疗研究中普遍存在。
  • 报告质量差且稀疏,决策所需患者重要结局未报告。
  • 紧急疫情不能将缺陷的方法和数据转化为可信结果,COVID-19仍缺乏足够把握度的对照稳健临床研究。

研究设计与样本

  • 文献检索与评述:检索MEDLINE和EMBASE(2019年至2020年4月3日)及medRxiv预印本库。
  • 检索词包括COVID-19、氯喹和羟氯喹等关键词组合。
  • 共纳入6项研究:3项随机对照试验和3项观察性研究,聚焦氯喹/羟氯喹(联合阿奇霉素)。

主要发现

  • 共发现6项氯喹/羟氯喹(联合阿奇霉素)相关研究,包括3项随机对照试验和3项观察性研究。
  • 对证据进行批判性评估后认为COVID-19研究方法学很差。
  • 筛查文献时观察到COVID-19潜在治疗研究整体存在同样问题。
  • 报告非常差且稀疏,患者重要结局未报告。

临床怎么用

  • 解读氯喹/羟氯喹等COVID-19治疗证据时需警惕方法学缺陷与报告稀疏。
  • 临床决策不应仅依据紧急疫情期间发表的低质量研究结果。
  • 应推动足够把握度的对照稳健临床研究以支持循证决策。

局限性

  • 检索截止2020年4月3日,仅覆盖早期COVID-19研究。
  • 以氯喹/羟氯喹为切入点评述,未系统量化全部COVID-19研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/BACKGROUND AND OBJECTIVES: Prior epidemics of high-mortality human coronaviruses, such as the acute respiratory syndrome coronavirus (SARS-CoV or SARS-1) in 2003, have driven the characterization of compounds that could be possibly active against the currently emerging novel coronavirus SARS-CoV-2 (COVID-19). Presently, no approved treatment or prophylaxis is available for COVID-19. We comment on the existing COVID-19 research methodologies in general and the published reporting. Given the media attention and claims of effectiveness, we chose chloroquine and hydroxychloroquine, in combination with azithromycin, as an area of COVID-19 research to examine. METHODS/STUDY DESIGN AND SETTING: MEDLINE and EMBASE electronic databases were searched from 2019 to present (April 3rd, 2020) using a mix of keywords such as COVID-19 and chloroquine and hydroxychloroquine. We also searched the largest clinical medicine preprint repository, medRxiv.org. RESULTS: We found 6 studies, 3 randomized control trials and 3 observational studies, focusing on chloroquine and hydroxychloroquine (with azithromycin). We critically appraised the evidence. CONCLUSION: We found that the COVID-19 research methodology is very poor in the area of chloroquine/hydroxychloroquine research. In screening the literature, we observed the same across COVID-19 research in relation to potential treatments. The reporting is very poor and sparse, and patient-important outcomes needed to discern decision-making priorities are not reported. We do understand the barriers to perform rigorous research in health care settings overwhelmed by a novel deadly disease. However, this emergency pandemic situation does not transform flawed methods and data into credible results. The adequately powered, comparative, and robust clinical research that is needed for optimal evidence-informed decision-making remains absent in COVID-19.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Alexander PE, Debono VB, Mammen MJ, et al. COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. J Clin Epidemiol. 2020. PMID: 32330521. doi:10.1016/j.jclinepi.2020.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。